Number of Baseline Melanoma Sites Predictive of OS in Dabrafenib/Trametinib Study

Source: Targeted Oncology, February 2017

Dabrafenib (Tafinlar) combined with trametinib (Mekinist) continued to demonstrate durable efficacy for patients with BRAF V600E/K-mutant melanoma across patient subgroups in a 3-year analysis of the phase III COMBI-d study, with the amount of baseline sites of metastasis identified as a predictor of overall survival (OS) ?36 months, according to findings presented at the 2016 Society for Melanoma Research (SMR) Congress.

The 3-year progression-free survival (PFS) rate with the combination was 22% (95% CI, 16-28) and the 3-year OS rate was 44% (95% CI, 37-51). Thirty-one patients (17%) had PFS of 36 months or longer, and 76 patients (41%) had OS of 36 months or longer. At the data cutoff, 40 patients (19%) remained on the combination regimen, including 23 of the 31 (31%) patients who experienced a PFS longer than 36 months, and 36 of 76 (47%) of those who experienced an OS longer than 36 months.